Besides, endometrial cancer treatment has provided new changes by incorporating biological, clinical, genomic, and clinico-pathologic characteristics of the women affected by this tumor, and recent studies showed that molecular targets such as L1CAM (L1 cell adhesion molecule) plays an important role as prognostic factor and could provide a potential useful tool for tailoring the need of adjuvant therapy (Giannini et al., 2024; Vizza et al., 2021). The gene discussed is L1CAM; the disease is neoplasm.